Overexpression of Semaphorin-3A and Semaphorin-4D in the Peripheral Blood from Newly Diagnosed Patients with Chronic Lymphocytic Leukemia
Background: Semaphorins play prominent roles in physiological and pathological processes such as vascular development, tumor growth and immune responses. Semaphorins have different roles in various kinds of cancers, but there is no study concerning their expression in the chronic lymphocytic leukemi...
Saved in:
| Published in | International journal of hematology- oncology and stem cell research Vol. 13; no. 1; pp. 25 - 34 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Iran
Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center
01.01.2019
Tehran University of Medical Sciences |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2008-2207 2008-3009 2008-2207 |
| DOI | 10.18502/ijhoscr.v13i1.322 |
Cover
| Abstract | Background: Semaphorins play prominent roles in physiological and pathological processes such as vascular development, tumor growth and immune responses. Semaphorins have different roles in various kinds of cancers, but there is no study concerning their expression in the chronic lymphocytic leukemia (CLL). This study aimed to assess the SEMA3A, SEMA4A and SEMA4D expression in patients with CLL.
Materials and Methods: Peripheral blood specimens were collected from 30 newly-diagnosed untreated patients with CLL and 30 healthy subjects as a control group. The SEMA3A, SEMA4A and SEMA4D expression was determined by real-time PCR method.
Results: The fold change expression of SEMA3A and SEMA4D was 7.58 ± 2.66 and 3.20 ± 0.99 in patients with CLL, and was 1.01 ± 0.31 and 1.00 ± 0.27 in healthy subjects, respectively. The CLL patients expressed higher amounts of SEMA3A and SEMA4D in comparison with healthy subjects (P<0.02 and P<0.03, respectively). The fold change expression of SEMA3A in patients with stage II (11.12 ± 5.35) was also higher than patients with stage I (4.49 ± 1.61, P<0.05). No significant difference was also observed in the expression of SEMA4A and SEMA4D between patients with stage I and stage II CLL. In both CLL and control groups, the fold change expression of SEMA3A was higher in men than in women (P<0.03 and P<0.02, respectively).
Conclusion: The results of the study indicated elevated expression of the SEMA3A and SEMA4D in patients with CLL. The SEMA3A expression was influenced by tumor stage and gender of participants. |
|---|---|
| AbstractList | Background: Semaphorins play prominent roles in physiological and pathological processes such as vascular development, tumor growth and immune responses. Semaphorins have different roles in various kinds of cancers, but there is no study concerning their expression in the chronic lymphocytic leukemia (CLL). This study aimed to assess the SEMA3A, SEMA4A and SEMA4D expression in patients with CLL.
Materials and Methods: Peripheral blood specimens were collected from 30 newly-diagnosed untreated patients with CLL and 30 healthy subjects as a control group. The SEMA3A, SEMA4A and SEMA4D expression was determined by real-time PCR method.
Results: The fold change expression of SEMA3A and SEMA4D was 7.58 ± 2.66 and 3.20 ± 0.99 in patients with CLL, and was 1.01 ± 0.31 and 1.00 ± 0.27 in healthy subjects, respectively. The CLL patients expressed higher amounts of SEMA3A and SEMA4D in comparison with healthy subjects (P<0.02 and P<0.03, respectively). The fold change expression of SEMA3A in patients with stage II (11.12 ± 5.35) was also higher than patients with stage I (4.49 ± 1.61, P<0.05). No significant difference was also observed in the expression of SEMA4A and SEMA4D between patients with stage I and stage II CLL. In both CLL and control groups, the fold change expression of SEMA3A was higher in men than in women (P<0.03 and P<0.02, respectively).
Conclusion: The results of the study indicated elevated expression of the SEMA3A and SEMA4D in patients with CLL. The SEMA3A expression was influenced by tumor stage and gender of participants. Background: Semaphorins play prominent roles in physiological and pathological processes such as vascular development, tumor growth and immune responses. Semaphorins have different roles in various kinds of cancers, but there is no study concerning their expression in the chronic lymphocytic leukemia (CLL). This study aimed to assess the SEMA3A, SEMA4A and SEMA4D expression in patients with CLL. Materials and Methods: Peripheral blood specimens were collected from 30 newly-diagnosed untreated patients with CLL and 30 healthy subjects as a control group. The SEMA3A, SEMA4A and SEMA4D expression was determined by real-time PCR method. Results: The fold change expression of SEMA3A and SEMA4D was 7.58 ± 2.66 and 3.20 ± 0.99 in patients with CLL, and was 1.01 ± 0.31 and 1.00 ± 0.27 in healthy subjects, respectively. The CLL patients expressed higher amounts of SEMA3A and SEMA4D in comparison with healthy subjects (P<0.02 and P<0.03, respectively). The fold change expression of SEMA3A in patients with stage II (11.12 ± 5.35) was also higher than patients with stage I (4.49 ± 1.61, P<0.05). No significant difference was also observed in the expression of SEMA4A and SEMA4D between patients with stage I and stage II CLL. In both CLL and control groups, the fold change expression of SEMA3A was higher in men than in women (P<0.03 and P<0.02, respectively). Conclusion: The results of the study indicated elevated expression of the SEMA3A and SEMA4D in patients with CLL. The SEMA3A expression was influenced by tumor stage and gender of participants.Background: Semaphorins play prominent roles in physiological and pathological processes such as vascular development, tumor growth and immune responses. Semaphorins have different roles in various kinds of cancers, but there is no study concerning their expression in the chronic lymphocytic leukemia (CLL). This study aimed to assess the SEMA3A, SEMA4A and SEMA4D expression in patients with CLL. Materials and Methods: Peripheral blood specimens were collected from 30 newly-diagnosed untreated patients with CLL and 30 healthy subjects as a control group. The SEMA3A, SEMA4A and SEMA4D expression was determined by real-time PCR method. Results: The fold change expression of SEMA3A and SEMA4D was 7.58 ± 2.66 and 3.20 ± 0.99 in patients with CLL, and was 1.01 ± 0.31 and 1.00 ± 0.27 in healthy subjects, respectively. The CLL patients expressed higher amounts of SEMA3A and SEMA4D in comparison with healthy subjects (P<0.02 and P<0.03, respectively). The fold change expression of SEMA3A in patients with stage II (11.12 ± 5.35) was also higher than patients with stage I (4.49 ± 1.61, P<0.05). No significant difference was also observed in the expression of SEMA4A and SEMA4D between patients with stage I and stage II CLL. In both CLL and control groups, the fold change expression of SEMA3A was higher in men than in women (P<0.03 and P<0.02, respectively). Conclusion: The results of the study indicated elevated expression of the SEMA3A and SEMA4D in patients with CLL. The SEMA3A expression was influenced by tumor stage and gender of participants. Background: Semaphorins play prominent roles in physiological and pathological processes such as vascular development, tumor growth and immune responses. Semaphorins have different roles in various kinds of cancers, but there is no study concerning their expression in the chronic lymphocytic leukemia (CLL). This study aimed to assess the SEMA3A, SEMA4A and SEMA4D expression in patients with CLL. Materials and Methods: Peripheral blood specimens were collected from 30 newly-diagnosed untreated patients with CLL and 30 healthy subjects as a control group. The SEMA3A, SEMA4A and SEMA4D expression was determined by real-time PCR method. Results: The fold change expression of SEMA3A and SEMA4D was 7.58 ± 2.66 and 3.20 ± 0.99 in patients with CLL, and was 1.01 ± 0.31 and 1.00 ± 0.27 in healthy subjects, respectively. The CLL patients expressed higher amounts of SEMA3A and SEMA4D in comparison with healthy subjects (P<0.02 and P<0.03, respectively). The fold change expression of SEMA3A in patients with stage II (11.12 ± 5.35) was also higher than patients with stage I (4.49 ± 1.61, P<0.05). No significant difference was also observed in the expression of SEMA4A and SEMA4D between patients with stage I and stage II CLL. In both CLL and control groups, the fold change expression of SEMA3A was higher in men than in women (P<0.03 and P<0.02, respectively). Conclusion: The results of the study indicated elevated expression of the SEMA3A and SEMA4D in patients with CLL. The SEMA3A expression was influenced by tumor stage and gender of participants. Background: Semaphorins play prominent roles in physiological and pathological processes such as vascular development, tumor growth and immune responses. Semaphorins have different roles in various kinds of cancers, but there is no study concerning their expression in the chronic lymphocytic leukemia (CLL). This study aimed to assess the SEMA3A, SEMA4A and SEMA4D expression in patients with CLL. Materials and Methods: Peripheral blood specimens were collected from 30 newly-diagnosed untreated patients with CLL and 30 healthy subjects as a control group. The SEMA3A, SEMA4A and SEMA4D expression was determined by real-time PCR method. Results: The fold change expression of SEMA3A and SEMA4D was 7.58 ± 2.66 and 3.20 ± 0.99 in patients with CLL, and was 1.01 ± 0.31 and 1.00 ± 0.27 in healthy subjects, respectively. The CLL patients expressed higher amounts of SEMA3A and SEMA4D in comparison with healthy subjects (P<0.02 and P<0.03, respectively). The fold change expression of SEMA3A in patients with stage II (11.12 ± 5.35) was also higher than patients with stage I (4.49 ± 1.61, P<0.05). No significant difference was also observed in the expression of SEMA4A and SEMA4D between patients with stage I and stage II CLL. In both CLL and control groups, the fold change expression of SEMA3A was higher in men than in women (P<0.03 and P<0.02, respectively). Conclusion: The results of the study indicated elevated expression of the SEMA3A and SEMA4D in patients with CLL. The SEMA3A expression was influenced by tumor stage and gender of participants. Semaphorins play prominent roles in physiological and pathological processes such as vascular development, tumor growth and immune responses. Semaphorins have different roles in various kinds of cancers, but there is no study concerning their expression in the chronic lymphocytic leukemia (CLL). This study aimed to assess the SEMA3A, SEMA4A and SEMA4D expression in patients with CLL. Peripheral blood specimens were collected from 30 newly-diagnosed untreated patients with CLL and 30 healthy subjects as a control group. The SEMA3A, SEMA4A and SEMA4D expression was determined by real-time PCR method. The fold change expression of SEMA3A and SEMA4D was 7.58 ± 2.66 and 3.20 ± 0.99 in patients with CLL, and was 1.01 ± 0.31 and 1.00 ± 0.27 in healthy subjects, respectively. The CLL patients expressed higher amounts of SEMA3A and SEMA4D in comparison with healthy subjects (P<0.02 and P<0.03, respectively). The fold change expression of SEMA3A in patients with stage II (11.12 ± 5.35) was also higher than patients with stage I (4.49 ± 1.61, P<0.05). No significant difference was also observed in the expression of SEMA4A and SEMA4D between patients with stage I and stage II CLL. In both CLL and control groups, the fold change expression of SEMA3A was higher in men than in women (P<0.03 and P<0.02, respectively). The results of the study indicated elevated expression of the SEMA3A and SEMA4D in patients with CLL. The SEMA3A expression was influenced by tumor stage and gender of participants. |
| Author | Sharifzadeh, Sedigheh Baghbani, Mohammad Reza Ranjbaran, Reza Jafarzadeh, Abdollah Monabati, Ahmad Seyyedi, Noorossadat Nemati, Maryam Parsa, Somayeh |
| AuthorAffiliation | 2 Diagnostic Laboratory Science and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran 1 Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran 6 Department of Immunology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran 5 Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran 4 Department of Laboratory Sciences, School of Para-Medicine, Kerman University of Medical Sciences, Kerman, Iran 3 Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran |
| AuthorAffiliation_xml | – name: 3 Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran – name: 2 Diagnostic Laboratory Science and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran – name: 5 Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran – name: 6 Department of Immunology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran – name: 4 Department of Laboratory Sciences, School of Para-Medicine, Kerman University of Medical Sciences, Kerman, Iran – name: 1 Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran |
| Author_xml | – sequence: 1 givenname: Somayeh surname: Parsa fullname: Parsa, Somayeh – sequence: 2 givenname: Sedigheh surname: Sharifzadeh fullname: Sharifzadeh, Sedigheh – sequence: 3 givenname: Ahmad surname: Monabati fullname: Monabati, Ahmad – sequence: 4 givenname: Noorossadat surname: Seyyedi fullname: Seyyedi, Noorossadat – sequence: 5 givenname: Reza surname: Ranjbaran fullname: Ranjbaran, Reza – sequence: 6 givenname: Mohammad Reza surname: Baghbani fullname: Baghbani, Mohammad Reza – sequence: 7 givenname: Maryam surname: Nemati fullname: Nemati, Maryam – sequence: 8 givenname: Abdollah surname: Jafarzadeh fullname: Jafarzadeh, Abdollah |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31205625$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks9uEzEQxleoiJbSF-CAfOSywX931xekkhaoFNFKwNlyvOOsw64d7E1KHoG3xk1SlHLAF4_GM7_PHn8vixMfPBTFa4InpBGYvnPLLiQTJxvCHJkwSp8VZxTjpqQU1ydH8WlxkdIS58UaiWvyojhlhGJRUXFW_L7dQIRfqwgpueBRsOgrDHrVheh8yS6R9u1xhl8h59HYAbqD6FYdRN2jD30ILbIxDOgL3PdbdOX0wocELbrTowM_JnTvxg5Nuxi8M2i2HTLPbMeHGNY_YHD6VfHc6j7BxWE_L75_vP42_VzObj_dTC9npWENo6VtbcOpxlRobIFoXM8ry0XLGKskBt7KqtINsxILw7gAELZuaculppLXFWPnxc2e2wa9VKvoBh23KmindokQF0rHfLEelDWW6zmntBaSz4nUnMos2lSECSKNzaz3e9ZqPR-gNfmleR5PoE9PvOvUImxUJUQta5oBbw-AGH6uIY1qcMlA32sPYZ0UpZxxKWVV59I3x1p_RR7_Mhc0-wITQ0oRrDJuzOMPD9KuVwSrnXPUwTlq5xyVnZNb6T-tj_T_NP0BPKXLqQ |
| CitedBy_id | crossref_primary_10_1155_2022_1384471 |
| ContentType | Journal Article |
| Copyright | Copyright : © International Journal of Hematology-Oncology and Stem Cell Research & Tehran University of Medical Sciences |
| Copyright_xml | – notice: Copyright : © International Journal of Hematology-Oncology and Stem Cell Research & Tehran University of Medical Sciences |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.18502/ijhoscr.v13i1.322 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2008-2207 |
| EndPage | 34 |
| ExternalDocumentID | oai_doaj_org_article_fcf4ab4227594b19a4290fe8613519cf PMC6557972 31205625 10_18502_ijhoscr_v13i1_322 |
| Genre | Journal Article |
| GroupedDBID | --- 2NT AAYXX ABDBF ACUHS ADBBV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION EBD EOJEC GROUPED_DOAJ HYE KQ8 M48 OBODZ OK1 PGMZT RPM M~E NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c3832-fdf842a025a0fe1a07b6f45d333690e4d966a83f905c345ee5f7d2d49a2947633 |
| IEDL.DBID | M48 |
| ISSN | 2008-2207 2008-3009 |
| IngestDate | Wed Aug 27 01:32:09 EDT 2025 Thu Aug 21 13:42:35 EDT 2025 Fri Jul 11 05:21:49 EDT 2025 Tue Jul 04 17:36:41 EDT 2023 Tue Jul 01 03:21:48 EDT 2025 Thu Apr 24 23:01:34 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | SEMA4A Chronic lymphocytic leukemia SEMA4D Semaphorins SEMA3A |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3832-fdf842a025a0fe1a07b6f45d333690e4d966a83f905c345ee5f7d2d49a2947633 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.18502/ijhoscr.v13i1.322 |
| PMID | 31205625 |
| PQID | 2243499967 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_fcf4ab4227594b19a4290fe8613519cf pubmedcentral_primary_oai_pubmedcentral_nih_gov_6557972 proquest_miscellaneous_2243499967 pubmed_primary_31205625 crossref_citationtrail_10_18502_ijhoscr_v13i1_322 crossref_primary_10_18502_ijhoscr_v13i1_322 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20190101 |
| PublicationDateYYYYMMDD | 2019-01-01 |
| PublicationDate_xml | – month: 1 year: 2019 text: 20190101 day: 1 |
| PublicationDecade | 2010 |
| PublicationPlace | Iran |
| PublicationPlace_xml | – name: Iran – name: Tehran, Iran |
| PublicationTitle | International journal of hematology- oncology and stem cell research |
| PublicationTitleAlternate | Int J Hematol Oncol Stem Cell Res |
| PublicationYear | 2019 |
| Publisher | Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center Tehran University of Medical Sciences |
| Publisher_xml | – name: Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center – name: Tehran University of Medical Sciences |
| SSID | ssj0000389071 ssib044740960 ssib008487754 ssib008507010 |
| Score | 2.0772755 |
| Snippet | Background: Semaphorins play prominent roles in physiological and pathological processes such as vascular development, tumor growth and immune responses.... Semaphorins play prominent roles in physiological and pathological processes such as vascular development, tumor growth and immune responses. Semaphorins have... Background: Semaphorins play prominent roles in physiological and pathological processes such as vascular development, tumor growth and immune responses.... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 25 |
| SubjectTerms | Chronic lymphocytic leukemia; Semaphorins; SEMA3A; SEMA4A; SEMA4D Original |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k14yUjcUNrEjzg-tpSqQhQqQaXeLMceawPbpKK7iP0J_GvGjrvaRQgu3KLEURzPN-MZe_wNIa-YRvUToStBO1sKW_uyA8lLqyuvgHtXJcr8kw_N8Zl4dy7PN0p9xZywiR54Gri94IKwnWBMSS26Wls0oFWAtkml5VyI1rfS1UYwlWwwzsM4eeZTMq2s2F7_ZTaiJu5-r3lf73LGtmaiRNj_Jy_z92TJjdnn6A65nd1Guj919y65AcM9cvMkb4zfJz8_IiThR85qHegY6Ce4sJezmF9X8n1qB795RxzSfqDo_NFThGCiFpjTg5jETuOBE4q2b76ih1MeHnh6OtGvXtG4bkszoy59v0IsjG61iNew_AoXvX1Azo7efn5zXOYqC6XD6JSVwYdWMIu-j8VxrW2luiYI6TnnGDmD8BgQ2ZYHXUnHhQSQQXnmhbZMC7RO_CHZGcYBHhOK0VDip7O-Q1vgm1YB4qB1jbLCNm1bkPp6xI3LFOSxEsbcxFAkSslkKZkkJYNSKsjr9TuXEwHHX1sfREGuW0by7HQDIWUypMy_IFWQl9cwMKhscQfFDjAurwz-HU8hoirIowkW60_xmkVnUhZEbQFmqy_bT4Z-lgi9GymVVuzJ_-j8U3ILfTo9rRI9IzuLb0t4jn7TonuRVOQXA-sZcQ priority: 102 providerName: Directory of Open Access Journals |
| Title | Overexpression of Semaphorin-3A and Semaphorin-4D in the Peripheral Blood from Newly Diagnosed Patients with Chronic Lymphocytic Leukemia |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31205625 https://www.proquest.com/docview/2243499967 https://pubmed.ncbi.nlm.nih.gov/PMC6557972 https://doaj.org/article/fcf4ab4227594b19a4290fe8613519cf |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6VVqp6QbxxgWiRuCEHex9e-4BQQhpViEIliNSbtfbuNobUbvNAzYU7_5rZ9SYkKOLAxbIcrxx7vvF8szv-BqFXJAP3Y6YIdVbKkMlYhYXmNJRZpISmqoycZP7Zp-R0xD5c8Is9tGp35B_gbGdqZ_tJjaaT7u3N8h04_Fvr8CmPyJvq27gBJ-v-iGkVdwGid9CBWy-ypXwbdD8Fdi42wicMFtGf8MeYYJbRr-dorPhc5HI2VyVAgY_47252X_YIHdKYWErBt8Kc6wawi8L-XYm5EdqG99Bdz0lxrwXRfbSn6wfo8Myvuj9Evz4D3vWtL5mtcWPwF30lr8e2eC-kPSxrtXmEDXBVY2CW-Bzw7XQLJrhvK-Sx_ZoFw4t1ssSDtshPK3zearvOsJ0Uxl6uF39cAtCacjm3-3rxXV9V8hEaDU--vj8NfQuHsITUl4RGmZQRCcRKRkbHMhJFYhhXlFJIyzVTkG3JlJos4iVlXGtuhCKKZZJkDF599DHar5taP0UYDOPE76QCSxGVpEIDyNIyEZLJJE0DFK-eeF56fXPbZmOS2zzHGiz3BsudwXIwWIBer8dct-oe_zy7bw25PtMqc7sDzfQy946em9IwWTBCBM9YEWcSAj7cepq4VoilCdDLFQxy8GS7PCNr3SxmOdwddfmnCNCTFhbrS61gFSCxBZit_7L9S12NnVp4wrnIBDn-75HP0BGwxKydd3qO9ufThX4BTGxedNBBrz_oDztuJqPjnM1uf578BvieM40 |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Overexpression+of+Semaphorin-3A+and+Semaphorin-4D+in+the+Peripheral+Blood+from+Newly+Diagnosed+Patients+with+Chronic+Lymphocytic+Leukemia&rft.jtitle=International+journal+of+hematology-+oncology+and+stem+cell+research&rft.au=Parsa%2C+Somayeh&rft.au=Sharifzadeh%2C+Sedigheh&rft.au=Monabati%2C+Ahmad&rft.au=Seyyedi%2C+Noorossadat&rft.date=2019-01-01&rft.pub=Tehran+University+of+Medical+Sciences%2C+Hematology-Oncology+and+Stem+Cell+Transplantation+Research+Center&rft.issn=2008-3009&rft.eissn=2008-2207&rft.volume=13&rft.issue=1&rft.spage=25&rft.epage=34&rft_id=info:doi/10.18502%2Fijhoscr.v13i1.322&rft_id=info%3Apmid%2F31205625&rft.externalDocID=PMC6557972 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2008-2207&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2008-2207&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2008-2207&client=summon |